Mercer Global Advisors
ABBV icon

Mercer Global Advisors’s AbbVie ABBV Stock Holding History

Mercer Global Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Buy
472,644
+42,013
+10% +$9.32M 0.15% 83
2025
Q4 		$100M Buy
430,631
+23,859
+6% +$5.44M 0.15% 89
2025
Q3 		$94.2M Sell
406,772
-160,307
-28% -$32.6M 0.16% 84
2025
Q2 		$105M Buy
567,079
+235,490
+71% +$43.8M 0.21% 65
2025
Q1 		$68.9M Sell
331,589
-2,892
-0.9% -$562K 0.16% 79
2024
Q4 		$59.4M Sell
334,481
-21,316
-6% -$3.92M 0.15% 83
2024
Q3 		$70.1M Sell
355,797
-130,228
-27% -$24.3M 0.16% 84
2024
Q2 		$56.9M Buy
486,025
+169,211
+53% +$28M 0.16% 87
2024
Q1 		$57.8M Buy
316,814
+23,042
+8% +$3.97M 0.16% 88
2023
Q4 		$45.5M Buy
293,772
+3,499
+1% +$510K 0.14% 108
2023
Q3 		$43.3M Sell
290,273
-10,812
-4% -$1.59M 0.16% 84
2023
Q2 		$40.6M Sell
301,085
-12,247
-4% -$1.8M 0.16% 95
2023
Q1 		$49.9M Sell
313,332
-4,726
-1% -$723K 0.23% 74
2022
Q4 		$51.4M Buy
318,058
+510
+0.2% +$78.2K 0.26% 65
2022
Q3 		$42.6M Buy
317,548
+873
+0.3% +$125K 0.25% 65
2022
Q2 		$48.5M Buy
316,675
+13,665
+5% +$2.09M 0.3% 58
2022
Q1 		$49.1M Buy
303,010
+6,491
+2% +$943K 0.29% 55
2021
Q4 		$40.1M Buy
296,519
+10,276
+4% +$1.21M 0.25% 67
2021
Q3 		$30.9M Buy
286,243
+27,426
+11% +$3.13M 0.22% 77
2021
Q2 		$29.2M Buy
258,817
+12,764
+5% +$1.44M 0.22% 78
2021
Q1 		$26.6M Buy
246,053
+60,574
+33% +$6.48M 0.24% 70
2020
Q4 		$19.9M Sell
185,479
-41
-0% -$3.94K 0.25% 64
2020
Q3 		$16.3M Buy
185,520
+7,569
+4% +$713K 0.24% 67
2020
Q2 		$17.5M Buy
177,951
+74,541
+72% +$6.56M 0.32% 55
2020
Q1 		$7.88M Sell
103,410
-16,588
-14% -$1.41M 0.17% 107
2019
Q4 		$10.6M Sell
119,998
-319
-0.3% -$26.5K 0.21% 95
2019
Q3 		$9.11M Buy
120,317
+9,850
+9% +$675K 0.21% 95
2019
Q2 		$8.03M Buy
110,467
+13,427
+14% +$1.06M 0.21% 97
2019
Q1 		$7.82M Buy
+97,040
New +$7.94M 0.28% 67

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mercer Global Advisors's ABBV Position: Q1 2026 in Review

Mercer Global Advisors increased its AbbVie (ABBV) stake by 9.8% in Q1 2026, buying an estimated $9.32M and bringing the position to 472,644 shares worth $103M. The position accounts for 0.15% of the portfolio, ranked #83.

Mercer Global Advisors first reported a position in ABBV in Q1 2019 and has held it in 29 quarters since. The position peaked at $105M in Q2 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Mercer Global Advisors held 472,644 shares of AbbVie worth $103M as of Q1 2026.
  • Mercer Global Advisors bought 42,013 AbbVie shares in Q1 2026, an estimated $9.32M.
  • AbbVie made up 0.15% of Mercer Global Advisors's portfolio in Q1 2026, its #83 holding.
  • Mercer Global Advisors first reported a position in AbbVie in Q1 2019 and has held it in 29 quarters since.
  • Mercer Global Advisors's AbbVie position peaked at $105M in Q2 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.